Innovita IVD – Precision in Every Test
Leading provider of rapid in vitro diagnostic solutions for infectious diseases, fertility, and chronic conditions. Trusted in over 70 countries with cutting-edge POCT technology and global certifications.
This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
Leading provider of rapid in vitro diagnostic solutions for infectious diseases, fertility, and chronic conditions. Trusted in over 70 countries with cutting-edge POCT technology and global certifications.
Innovita Biological Technology Co., Ltd. (collectively known as “INNOVITA”) is a biotechnology company focusing on the research, development, production, and sales of in vitro diagnostic POCT products. Founded in 2006, Innovita operates across Beijing, Tangshan, and Guangzhou, with a global footprint in over 70 countries.
On July 28, 2022, INNOVITA completed its initial public offering, with shares trading on the SSE STAR Market. The company is committed to advancing global healthcare through innovative diagnostic solutions.
Comprehensive diagnostic solutions across key health domains with high sensitivity, rapid results, and global regulatory compliance.
Antigen, antibody, neutralizing antibody, and nucleic acid tests with CE certification and high clinical accuracy.
Flu A/B, RSV, MP/CP, and multi-pathogen IgM combo tests using colloidal gold and PCR technologies.
Rotavirus, Adenovirus, Norovirus, and H. Pylori antigen/antibody detection kits.
HCG pregnancy and LH ovulation rapid tests for home and clinical use.
Malaria, Dengue, Zika, Chikungunya, and other vector-borne disease detection.
HAV IgM and HEV IgM rapid tests for early diagnosis of viral hepatitis.
High-performance rapid tests with fast turnaround and global certifications.
Clinical sensitivity up to 98.7% and specificity of 100% in key assays.
Most tests deliver results in 10–15 minutes for timely clinical decisions.
CE, ISO 13485, GMP, and FDA-aligned standards across all manufacturing.
Yes, many of our rapid tests, including the 2019-nCoV antigen test, carry CE certification for use in Europe.
Yes, the anterior nasal swab version is designed for self-testing with high accuracy and ease of use.
Most rapid tests deliver results within 10 to 15 minutes.
Yes, we work with global distributors and provide competitive pricing. Please visit the official site for inquiries.
For product inquiries, distributor partnerships, or technical support, please visit our official website.
Visit Official WebsiteNotice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact [email protected] via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系[email protected] 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact [email protected]
如果您是其他域名合作 也请联系[email protected]